A Study Evaluating the Efficacy and Safety of the LentiGlobin® BB305 Drug Product in Participants With Transfusion-Dependent β-Thalassemia
Completed · Phase 3 · NCT03207009
Conditions: Beta-Thalassemia
At a glance
- Research payments reported, 2025
- $24,220
- U.S. investigators named
- 1
- Sites paid
- 1
- Planned or actual enrollment
- 19
About the trial
- Sponsor
- Genetix Biotherapeutics Inc.
- Tested
- LentiGlobin BB305 Drug Product (genetic)
- Dates
- Started 2017-06-08; completion 2022-11-15
- Results posted
- Yes
This is a single-arm, multi-site, single-dose, Phase 3 study in approximately 18 participants less than or equal to (\<=) 50 years of age with transfusion-dependent β-thalassemia (TDT), who have a β0/β0, β0/IVS-I-110, or IVS-I-110/IVS-I-110 genotype. The study will evaluate the efficacy and safety of autologous hematopoietic stem cell transplantation (HSCT) using LentiGlobin BB305 Drug Product.
From ClinicalTrials.gov, last updated 2024-03-07. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Genetix Biotherapeutics Inc reported $24,220 in research payments for this study in 2025 (2 payments).
Products named: Zynteglo
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.